業績紹介

2021年 論文

  • Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
    Takamatsu K, Tanaka N, Hakozaki K, Takahashi R, Teranishi Y, Murakami T, Kufukihara R, Niwa N, Mikami S, Shinojima T, Sasaki T, Sato Y, Kume H, Ogawa S, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Sawada K, Imamura T, Mizuno R, Oya M.
    Nat Commun. 2021 Sep 20;12(1):5547. doi: 10.1038/s41467-021-25865-0.
  • Germline Whole-Gene Deletion of FH Diagnosed from Tumor Profiling.
    Ueki A, Sugano K, Misu K, Aimono E, Nakamura K, Tanishima S, Tanaka N, Mikami S, Hirasawa A, Ando M, Yoshida T, Oya M, Nishihara H, Kosaki K.
    Int J Mol Sci. 2021 Jul 26;22(15):7962. doi: 10.3390/ijms22157962.
  • MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells.
    Hagiwara M, Yasumizu Y, Yamashita N, Rajabi H, Fushimi A, Long MD, Li W, Bhattacharya A, Ahmad R, Oya M, Liu S, Kufe D.
    Cancer Res. 2021 Feb 15;81(4):1111-1122. doi: 10.1158/0008-5472.CAN-20-2588. Epub 2020 Dec 15.
  • ASO Author Reflections: Previous History of Non-urothelial Malignancy May Provide Predictive Information of Worse Clinical Outcome for Initially Diagnosed Non-Muscle Invasive Bladder Cancer.
    Kufukihara R, Kikuchi E, Ogihara K, Shigeta K, Oya M.
    Ann Surg Oncol. 2021 Sep;28(9):5360-5361. doi: 10.1245/s10434-021-09787-1. Epub 2021 Mar 27.
  • ASO Author Reflections: Discussing the Oncological Feasibility of Performing Pure Laparoscopic Radical Nephroureterectomy for Upper-Tract Urothelial Carcinoma Patients: Results from a Multi-institution Collaborative Study Adjusted by Propensity Score Matching.
    Shigeta K, Matsumoto K, Oya M.
    Ann Surg Oncol. 2021 Jan;28(1):474-475. doi: 10.1245/s10434-020-09048-7. Epub 2020 Aug 19.
  • The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
    Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, Tanaka N, Takeda T, Kosaka T, Mizuno R, Mikami S, Kikuchi E, Oya M.
    Cancer Sci. 2021 Mar;112(3):1084-1094. doi: 10.1111/cas.14782. Epub 2021 Jan 11.
  • Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.
    Hongo H, Kosaka T, Suzuki Y, Mikami S, Fukada J, Oya M.
    Sci Rep. 2021 Nov 15;11(1):22284. doi: 10.1038/s41598-021-01697-2.
  • Risk factors for haemodynamic instability and its prolongation during laparoscopic adrenalectomy for pheochromocytoma.
    Takeda T, Hakozaki K, Yanai Y, Masuda T, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Kurihara I, Asanuma H, Itoh H, Oya M.
    Clin Endocrinol (Oxf). 2021 Nov;95(5):716-726. doi: 10.1111/cen.14557. Epub 2021 Jul 19.
  • Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer.
    Hakozaki K, Kikuchi E, Ogihara K, Shigeta K, Abe T, Miyazaki Y, Kaneko G, Maeda T, Yoshimine S, Kanai K, Ide H, Shirotake S, Oyama M, Mizuno R, Oya M.
    Jpn J Clin Oncol. 2021 Feb 8;51(2):287-295. doi: 10.1093/jjco/hyaa168.
  • Evaluation of Gleason Grade Group 5 in a Contemporary Prostate Cancer Grading System and Literature Review.
    Kamitani R, Matsumoto K, Kosaka T, Takeda T, Hashiguchi A, Tanaka N, Morita S, Mizuno R, Shinojima T, Asanuma H, Oya M.
    Clin Genitourin Cancer. 2021 Feb;19(1):69-75.e5. doi: 10.1016/j.clgc.2020.08.001. Epub 2020 Aug 7.
  • Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma.
    Hakozaki K, Tanaka N, Takamatsu K, Takahashi R, Yasumizu Y, Mikami S, Shinojima T, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Mizuno R, Oya M.
    Br J Cancer. 2021 Nov;125(11):1533-1543. doi: 10.1038/s41416-021-01559-8. Epub 2021 Oct 5.
  • Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer.
    Takayama KI, Kosaka T, Suzuki T, Hongo H, Oya M, Fujimura T, Suzuki Y, Inoue S.
    Nat Commun. 2021 Jun 18;12(1):3766. doi: 10.1038/s41467-021-23974-4.
  • Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy.
    Matsumoto K, Niwa N, Kosaka T, Takeda T, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Shinojima T, Asanuma H, Oya M.
    Int J Clin Oncol. 2021 Sep;26(9):1722-1728. doi: 10.1007/s10147-021-01942-8. Epub 2021 Jun 4.
  • Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer.
    Watanabe K, Kosaka T, Hongo H, Oya M.
    Sci Rep. 2021 Apr 16;11(1):8367. doi: 10.1038/s41598-021-87758-y.
  • CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer.
    Yanai Y, Kosaka T, Mikami S, Hongo H, Yasumizu Y, Takeda T, Matsumoto K, Miyauchi J, Kitano S, Oya M.
    Sci Rep. 2021 Nov 18;11(1):22495. doi: 10.1038/s41598-021-01900-4.
  • Can random bladder biopsies be eliminated after bacillus Calmette-Guérin therapy against carcinoma in situ?
    Takamatsu K, Matsumoto K, Kikuchi E, Ogihara K, Hayakawa N, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Asanuma H, Mikami S, Oyama M, Oya M.
    Int Urol Nephrol. 2021 Mar;53(3):465-469. doi: 10.1007/s11255-020-02667-9. Epub 2020 Oct 6.
  • Guideline adherence for radical cystectomy significantly affects survival outcomes in non-muscle-invasive bladder cancer patients.
    Kayama E, Shigeta K, Kikuchi E, Ogihara K, Hakozaki K, Iwasawa T, Kamisawa K, Kanai K, Ide H, Hara S, Mizuno R, Oya M.
    Jpn J Clin Oncol. 2021 Aug 1;51(8):1303-1312. doi: 10.1093/jjco/hyab060.
  • Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma.
    Uemura M, Nakaigawa N, Sassa N, Tatsugami K, Harada K, Yamasaki T, Matsubara N, Yoshimoto T, Nakagawa Y, Fukuyama T, Oya M, Shinohara N, Uemura H, Tsuzuki T.
    Int J Clin Oncol. 2021 Nov;26(11):2073-2084. doi: 10.1007/s10147-021-01993-x. Epub 2021 Jul 21.
  • First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion.
    Shojo K, Kosaka T, Nakamura K, Hongo H, Kobayashi H, Mikami S, Nishihara H, Oya M.
    IJU Case Rep. 2021 Mar 17;4(3):176-179. doi: 10.1002/iju5.12274. eCollection 2021 May.
  • Bullous pemphigoid in patients receiving peritoneal dialysis: a case series and a literature survey.
    Morimoto K, Yoshida T, Washida N, Uchiyama K, Nakayama T, Itoh H, Oya M.
    Ren Fail. 2021 Dec;43(1):651-657. doi: 10.1080/0886022X.2021.1910045.
  • Effects of transurethral resection under general anesthesia on tumor recurrence in non-muscle invasive bladder cancer.
    Baba Y, Kikuchi E, Shigeta K, Ogihara K, Matsushima M, Nishimoto Y, Murata Y, Asakura H, Oyama M, Mizuno R, Oya M.
    Int J Clin Oncol. 2021 Nov;26(11):2094-2103. doi: 10.1007/s10147-021-02000-z. Epub 2021 Aug 6.
  • Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
    Matsumoto K, Niwa N, Hagiwara M, Kosaka T, Takeda T, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Shinojima T, Hara S, Asanuma H, Oya M.
    Int J Clin Oncol. 2021 Apr;26(4):744-752. doi: 10.1007/s10147-020-01839-y. Epub 2021 Jan 2.
  • On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma.
    Takamatsu K, Mizuno R, Baba Y, Yasumizu Y, Tanaka N, Shirotake S, Takeda T, Morita S, Matsumoto K, Kosaka T, Asanuma H, Oyama M, Mikami S, Oya M.
    Int J Clin Oncol. 2021 Aug;26(8):1500-1505. doi: 10.1007/s10147-021-01930-y. Epub 2021 Jun 8.
  • Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery.
    Anno T, Kikuchi E, Shigeta K, Ogihara K, Watanabe K, Yanai Y, Takamatsu K, Hasegawa S, Masuda T, Oyama M, Mizuno R, Oya M.
    Jpn J Clin Oncol. 2021 May 28;51(6):984-991. doi: 10.1093/jjco/hyab003.
  • Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma.
    Murakami T, Kikuchi E, Ide H, Umezawa Y, Takahashi T, Izawa M, Hakozaki K, Shigeta K, Ogihara K, Kobayashi H, Kanai K, Maeda T, Yoshimine S, Mizuno R, Nishimoto K, Oya M.
    BJUI Compass. 2021 Mar 9;2(5):322-330. doi: 10.1002/bco2.81. eCollection 2021 Sep.
  • Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.
    Murakami T, Tanaka N, Takamatsu K, Hakozaki K, Fukumoto K, Masuda T, Mikami S, Shinojima T, Kakimi K, Tsunoda T, Sawada K, Imamura T, Mizuno R, Oya M.
    Cancer Immunol Immunother. 2021 Oct;70(10):3001-3013. doi: 10.1007/s00262-021-03006-2. Epub 2021 Jul 14.
  • Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer.
    Kufukihara R, Kikuchi E, Ogihara K, Shigeta K, Yanai Y, Takamatsu K, Ide H, Oyama M, Asakura H, Mizuno R, Oya M.
    Ann Surg Oncol. 2021 Sep;28(9):5349-5359. doi: 10.1245/s10434-021-09750-0. Epub 2021 Mar 5.
  • MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
    Hagiwara M, Fushimi A, Yamashita N, Bhattacharya A, Rajabi H, Long MD, Yasumizu Y, Oya M, Liu S, Kufe D.
    Oncogene. 2021 Jul;40(30):4930-4940. doi: 10.1038/s41388-021-01899-y. Epub 2021 Jun 23.
  • Frequent azoospermia in patients with testicular germ cell cancer and a history of cryptorchidism: a report of nine cases and review of the literature.
    Hagiuda J, Nakagawa K, Oya M.
    Syst Biol Reprod Med. 2021 Jun;67(3):189-192. doi: 10.1080/19396368.2020.1867666. Epub 2021 Feb 25.
  • Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case.
    Izawa M, Kosaka T, Nakamura K, Oba J, Hishida T, Hongo H, Mikami S, Nishihara H, Oya M.
    IJU Case Rep. 2020 Oct 15;4(1):14-17. doi: 10.1002/iju5.12224. eCollection 2021 Jan.
  • A Case of New-Onset Systemic Lupus Erythematosus With Serositis in a Maintenance Hemodialysis Patient.
    Kosugi S, Yoshida T, Yoshimoto N, Itoh H, Oya M.
    Clin Med Insights Case Rep. 2021 Oct 27;14:11795476211056172. doi: 10.1177/11795476211056172. eCollection 2021.
  • Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade Do Not Coincide within One Lesion.
    Matsumoto K, Omura M, Takeda T, Kosaka T, Hashiguchi A, Takamatsu K, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Asanuma H, Oya M.
    J Urol. 2021 Aug;206(2):338-345. doi: 10.1097/JU.0000000000001765. Epub 2021 Apr 5.
  • Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening.
    Hongo H, Kosaka T, Suzuki Y, Oya M.
    Prostate Cancer Prostatic Dis. 2021 Sep 30. doi: 10.1038/s41391-021-00426-0. Online ahead of print.
  • Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history.
    Ide H, Kikuchi E, Ogihara K, Niwa N, Shigeta K, Masuda T, Baba Y, Mizuno R, Oya M.
    Sci Rep. 2021 Oct 19;11(1):20675. doi: 10.1038/s41598-021-00184-y.
  • Diagnostic value of texture analysis of apparent diffusion coefficient maps for differentiating fat-poor angiomyolipoma from non-clear-cell renal cell carcinoma.
    Arita Y, Yoshida S, Kwee TC, Akita H, Okuda S, Iwaita Y, Mukai K, Matsumoto S, Ueda R, Ishii R, Mizuno R, Fujii Y, Oya M, Jinzaki M.
    Eur J Radiol. 2021 Oct;143:109895. doi: 10.1016/j.ejrad.2021.109895. Epub 2021 Aug 5.
  • Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan.
    Kobayashi H, Kosaka T, Mikami S, Kimura T, Hongo H, Kosugi M, Sato Y, Oya M.
    BMJ Open. 2021 Nov 24;11(11):e056439. doi: 10.1136/bmjopen-2021-056439.
  • Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions.
    Arita Y, Shigeta K, Akita H, Suzuki T, Kufukihara R, Kwee TC, Ishii R, Mikami S, Okuda S, Kikuchi E, Oya M, Jinzaki M.
    Eur Radiol. 2021 Feb;31(2):875-883. doi: 10.1007/s00330-020-07153-5. Epub 2020 Aug 23.
  • Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
    Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M.
    Jpn J Clin Oncol. 2021 Nov 1;51(11):1656-1664. doi: 10.1093/jjco/hyab114.
  • Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
    Uemura H, Matsushima H, Kobayashi K, Mizusawa H, Nishimatsu H, Fizazi K, Smith M, Shore N, Tammela T, Tabata KI, Matsubara N, Iinuma M, Uemura H, Oya M, Momma T, Kawakita M, Fukasawa S, Kobayashi T, Kuss I, Le Berre MA, Snapir A, Sarapohja T, Suzuki K.
    Int J Clin Oncol. 2021 Mar;26(3):578-590. doi: 10.1007/s10147-020-01824-5. Epub 2020 Nov 23.
  • Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).
    Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kabu K, Tajima Y, Oya M.
    Jpn J Clin Oncol. 2021 May 28;51(6):966-975. doi: 10.1093/jjco/hyaa266.
  • Evaluating the Oncological Outcomes of Pure Laparoscopic Radical Nephroureterectomy Performed for Upper-Tract Urothelial Carcinoma Patients: A Multicenter Cohort Study Adjusted by Propensity Score Matching.
    Shigeta K, Matsumoto K, Takeda T, Hattori S, Kaneko G, Matsushima M, Abe T, Tanaka N, Mizuno R, Asanuma H, Kikuchi E, Oya M.
    Ann Surg Oncol. 2021 Jan;28(1):465-473. doi: 10.1245/s10434-020-09046-9. Epub 2020 Aug 25.
  • Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports.
    Takahashi R, Yoshida T, Morimoto K, Kondo Y, Kikuchi J, Saito S, Ishigaki S, Kaneko Y, Takeuchi T, Itoh H, Oya M.
    Clin Med Insights Case Rep. 2021 Jul 27;14:11795476211036322. doi: 10.1177/11795476211036322. eCollection 2021.
  • Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification.
    Daimon T, Kosaka T, Hongo H, Aimono E, Nakamura K, Mikami S, Nishihara H, Oya M.
    IJU Case Rep. 2021 May 5;4(4):216-219. doi: 10.1002/iju5.12287. eCollection 2021 Jul.
  • A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing.
    Hongo H, Kosaka T, Nakatsuka S, Oya M.
    Int Cancer Conf J. 2021 Apr 13;10(3):174-180. doi: 10.1007/s13691-021-00482-2. eCollection 2021 Jul.
  • A first Japanese case of BRCA2 and RB1 co-loss organ-confined prostate cancer successfully treated by radical prostatectomy.
    Matsumoto K, Kosaka T, Nakamura K, Nishihara H, Oya M.
    Int Cancer Conf J. 2021 Mar 27;10(3):170-173. doi: 10.1007/s13691-021-00469-z. eCollection 2021 Jul.
  • Cranial nerve palsy caused by metastasis to the skull base in patients with castration-resistant prostate cancer: Three case reports.
    Yasumizu Y, Kosaka T, Hongo H, Mizuno R, Oya M.
    IJU Case Rep. 2021 Jan 21;4(2):108-111. doi: 10.1002/iju5.12255. eCollection 2021 Mar.
  • Transient hypercalcemia in a patient with SAPHO syndrome.
    Yoshida T, Oya M.
    J Gen Fam Med. 2021 Jul 7;23(1):44-46. doi: 10.1002/jgf2.480. eCollection 2022 Jan.
  • A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
    Kobayashi H, Kosaka T, Nakamura K, Shojo K, Hongo H, Mikami S, Nishihara H, Oya M.
    BMC Med Genomics. 2021 Oct 9;14(1):245. doi: 10.1186/s12920-021-01093-9.
  • Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
    Yamashita R, Nakamura M, Okayama Y, Kawase M, Muraoka N, Fujita A, Notsu A, Asakura K, Hashizume A, Shinsaka H, Matsuzaki M, Niwakawa M, Oya M.
    Int J Urol. 2022 Mar;29(3):259-264. doi: 10.1111/iju.14760. Epub 2021 Dec 9.
  • Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
    Yoshida T, Morimoto K, Kaburagi N, Fujino T, Takemitsu TY, Yamashita N, Oya M.
    Int Urol Nephrol. 2022 Apr;54(4):861-872. doi: 10.1007/s11255-021-02952-1. Epub 2021 Jul 15.
  • Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Arita Y, Akita H, Jinzaki M, Kikuchi E, Oya M.
    Urol Oncol. 2022 Mar;40(3):105.e19-105.e26. doi: 10.1016/j.urolonc.2021.07.029. Epub 2021 Aug 25.
  • Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study.
    Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, Kakehi Y, Naito S, Nonomura N, Ogawa O, Oya M, Suzuki K, Saito A, Uno S, Akaza H.
    BJUI Compass. 2021 Aug 20;3(1):26-36. doi: 10.1002/bco2.103. eCollection 2022 Jan.
  • First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.
    Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M.
    IJU Case Rep. 2021 Oct 20;5(1):41-44. doi: 10.1002/iju5.12383. eCollection 2022 Jan.
  • Amiodarone-induced multiple organ damage in an Alström syndrome patient with end-stage renal disease and hepatic cirrhosis.
    Torimitsu T, Yoshida T, Nishi S, Itoh H, Oya M.
    CEN Case Rep. 2022 Feb;11(1):11-16. doi: 10.1007/s13730-021-00621-x. Epub 2021 Jul 5.
  • The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
    Hagiwara M, Fushimi A, Matsumoto K, Oya M.
    Eur Urol. 2022 Feb;81(2):145-148. doi: 10.1016/j.eururo.2021.09.024. Epub 2021 Oct 6.
  • Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: Comparison with diagnostic cystoscopy.
    Kufukihara R, Kikuchi E, Shigeta K, Ogihara K, Arita Y, Akita H, Suzuki T, Abe T, Mizuno R, Jinzaki M, Oya M.
    Urol Oncol. 2022 Feb;40(2):61.e1-61.e8. doi: 10.1016/j.urolonc.2021.07.005. Epub 2021 Jul 29.
業績紹介
慶應義塾大学泌尿器科学教室

160-8582 東京都新宿区信濃町35

TEL: 03-3353-1211（代表）

FAX: 03-3225-1985

  • 臨床研究へのご協力のお願い
  • NCDへのご協力のお願い
  • 慶應義塾大学病院
  • 慶應義塾大学医学部・医学研究科
  • 慶應義塾大学医学部 卒後臨床研修 専修医研修センター
  • 100周年
  • 慶應義塾大学
  • 三四会